

Registered number: 09559128

AIMMUNE THERAPEUTICS UK LIMITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2017



AIMMUNE THERAPEUTICS UK LIMITED

COMPANY INFORMATION

Directors	Stephen Dilly Susan E Barrowcliffe Douglas T Sheehy
Company secretary	Crowe Clark Whitehill
Registered number	09559128
Registered office	Carrick House Lypiatt Road Cheltenham Gloucestershire United Kingdom GL50 2QJ
Independent auditor	Randall and Payne LLP Chargrove House Shurdington Road Cheltenham Gloucestershire GL51 4GA

AIMMUNE THERAPEUTICS UK LIMITED

CONTENTS

	Page
Statement of financial position.	1 - 2
Notes to the financial statements	3 - 10

AIMMUNE THERAPEUTICS UK LIMITED
REGISTERED NUMBER: 09559128

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2017


	Note	2017 \$	2016 \$
Fixed assets			
Tangible assets	4	74,034	51,005
		<u>74,034</u>	<u>51,005</u>
Current assets			
Debtors: amounts falling due within one year	5	4,751,232	1,791,701
Cash at bank and in hand		1,162,144	264,338
		<u>5,913,376</u>	<u>2,056,039</u>
Creditors: amounts falling due within one year	6	(3,013,205)	(982,163)
Net current assets		<u>2,900,171</u>	<u>1,073,876</u>
Total assets less current liabilities		<u>2,974,205</u>	<u>1,124,881</u>
Provisions for liabilities			
Deferred tax	7	(12,586)	(8,671)
		<u>(12,586)</u>	<u>(8,671)</u>
Net assets		<u>2,961,619</u>	<u>1,116,210</u>
Capital and reserves			
Called up share capital		1,528	1,528
Equity settled share based payments	8	2,941,348	1,046,043
Profit and loss account		18,743	68,639
Shareholder's funds		<u>2,961,619</u>	<u>1,116,210</u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:


.....
Douglas T Sheehy

AIMMUNE THERAPEUTICS UK LIMITED
REGISTERED NUMBER: 09559128

STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2017

Director

Date: 11 December 2018

The notes on pages 3 to 10 form part of these financial statements.

AIMMUNE THERAPEUTICS UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

1. General information

Aimmune Therapeutics UK Limited is a private company limited by shares, incorporated and domiciled in the United Kingdom. The address of the registered office is Carrick House, Lypiatt Road, Cheltenham, Gloucestershire, United Kingdom, GL50 2QJ.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the company's accounting policies.

The following principal accounting policies have been applied:

2.2 Financial reporting standard 102 - reduced disclosure exemptions

The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

- the requirements of Section 4 Statement of Financial Position paragraph 4.12(a)(iv);
- the requirements of Section 7 Statement of Cash Flows;
- the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);
- the requirements of Section 11 Financial Instruments paragraphs 11.41(b), 11.41(c), 11.41(e), 11.41(f), 11.42, 11.44 to 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c);
- the requirements of Section 12 Other Financial Instruments paragraphs 12.26 to 12.27, 12.29(a), 12.29(b) and 12.29A;
- the requirements of Section 26 Share-based Payment paragraphs 26.18(b), 26.19 to 26.21 and 26.23;
- the requirements of Section 33 Related Party Disclosures paragraph 33.7.

This information is included in the consolidated financial statements of Aimmune Therapeutics Inc. as at 31 December 2017 and these financial statements may be obtained from 8000 Marina Boulevard, Suite 300, Brisbane, California 94005, United States of America.

2.3 Going concern

The directors have a reasonable expectation that the company has adequate resources to continue in operational existence for a period of at least twelve months from the date of signing this report.

The company relies on the continued support from its parent company Aimmune Therapeutics (Bermuda) Ltd which has confirmed that it will continue to provide this for the foreseeable future. On that basis, the directors continue to adopt the going concern basis of accounting in preparing the annual financial statements.

AIMMUNE THERAPEUTICS UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

2. Accounting policies (continued)

2.4 Foreign currency translation

Functional and presentation currency

The company's functional and presentational currency is USD.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of comprehensive income except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of comprehensive income within 'finance income or costs'. All other foreign exchange gains and losses are presented in the Statement of comprehensive income within 'other operating income'.

2.5 Revenue recognition

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

The company is contracted by its parent company, Aimmune Therapeutics (Bermuda) Ltd to deliver research and development services under an intercompany agreement. The company is remunerated by its parent for these services.

2.6 Operating leases: the company as lessee

Rentals paid under operating leases are charged to the Statement of comprehensive income on a straight line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

2.7 Interest income

Interest income is recognised in the Statement of comprehensive income using the effective interest method.

AIMMUNE THERAPEUTICS UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

2. Accounting policies (continued)

2.8 Pensions

Defined contribution pension plan

The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations.

The contributions are recognised as an expense in the Statement of comprehensive income when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the company in independently administered funds.

2.9 Share based payments

Where share options are awarded to employees, the fair value of the options at the date of grant is charged to the Statement of comprehensive income over the vesting period. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at each Statement of financial position date so that, ultimately, the cumulative amount recognised over the vesting period is based on the number of options that eventually vest. Market vesting conditions are factored into the fair value of the options granted. The cumulative expense is not adjusted for failure to achieve a market vesting condition.

The fair value of the award also takes into account non-vesting conditions. These are either factors beyond the control of either party (such as a target based on an index) or factors which are within the control of one or other of the parties (such as the company keeping the scheme open or the employee maintaining any contributions required by the scheme).

Where the terms and conditions of options are modified before they vest, the increase in the fair value of the options, measured immediately before and after the modification, is also charged to Statement of comprehensive income over the remaining vesting period.

Where equity instruments are granted to persons other than employees, the Statement of comprehensive income is charged with fair value of goods and services received.

AIMMUNE THERAPEUTICS UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

2. Accounting policies (continued)

2.10 Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in the Statement of comprehensive income, except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the Statement of financial position date, except that:

- The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
- Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

2.11 Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

The estimated useful lives range as follows:

Fixtures and fittings	- 3 years
Office equipment	- 3 years

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Statement of comprehensive income.

2.12 Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

AIMMUNE THERAPEUTICS UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017

2. Accounting policies (continued)

2.13 Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.14 Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.15 Holiday pay accrual

A liability is recognised to the extent of any unused holiday pay entitlement which is accrued at the Statement of financial position date and carried forward to future periods. This is measured at the undiscounted salary cost of the future holiday entitlement so accrued at the Statement of financial position date.

2.16 Provisions for liabilities

Provisions are made where an event has taken place that gives the company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.

Provisions are charged as an expense to the Statement of comprehensive income in the year that the company becomes aware of the obligation, and are measured at the best estimate at the Statement of financial position date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.

When payments are eventually made, they are charged to the provision carried in the Statement of financial position.

2.17 Financial instruments

The company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

3. Employees

The average monthly number of employees, including directors, during the year was 17 (2016 - 9).

AIMMUNE THERAPEUTICS UK LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017**

4. Tangible fixed assets

	Fixtures and fittings \$	Office equipment \$	Total \$
Cost or valuation			
At 1 January 2017	15,913	59,435	75,348
Additions	2,507	54,893	57,400
At 31 December 2017	<u>18,420</u>	<u>114,328</u>	<u>132,748</u>
Depreciation			
At 1 January 2017	5,064	19,279	24,343
Charge for the year on owned assets	5,762	28,609	34,371
At 31 December 2017	<u>10,826</u>	<u>47,888</u>	<u>58,714</u>
Net book value			
At 31 December 2017	<u>7,594</u>	<u>66,440</u>	<u>74,034</u>
At 31 December 2016	<u>10,849</u>	<u>40,156</u>	<u>51,005</u>

5. Debtors

	2017 \$	2016 \$
Amounts owed by group undertakings	3,997,062	1,561,479
Other debtors	754,170	230,222
	<u>4,751,232</u>	<u>1,791,701</u>

AIMMUNE THERAPEUTICS UK LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017**

6. Creditors: Amounts falling due within one year

	2017 \$	2016 \$
Trade creditors	437,927	119,194
Amounts owed to group undertakings	-	328,604
Corporation tax	144,369	35,894
Other taxation and social security	38,355	12,888
Other creditors	52,149	17,991
Accruals and deferred income	2,340,405	467,592
	<u>3,013,205</u>	<u>982,163</u>

7. Deferred taxation

	2017 \$	2016 \$
At beginning of year	(8,671)	-
Charged to profit or loss	(3,915)	(8,671)
At end of year	<u>(12,586)</u>	<u>(8,671)</u>

The provision for deferred taxation is made up as follows:

	2017 \$	2016 \$
Accelerated capital allowances	(12,586)	(8,671)
	<u>(12,586)</u>	<u>(8,671)</u>

8. Share based payments

The company participates in a share option scheme for all employees. Options are exercisable on the shares of the ultimate parent company at a price equal to the estimated fair value of the ultimate parent company's shares on the date of the grant.

The vesting period is four years. If the options remain unexercised after a period of ten years from the date of the grant the options expire. Options are forfeited if the employee leaves the company before the options vest.

AIMMUNE THERAPEUTICS UK LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017**

9. Pension commitments

The company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund and amounted to \$48,478 (2016 - \$20,972). Contributions totalling \$nil (2016 - \$nil) were payable to the fund at the reporting date.

10. Related party transactions

The company has taken advantage of the exemption available under section 33.1A of Financial Reporting Standard 102, not to disclose transactions with other wholly owned members of this group.

11. Controlling party

The company is a wholly owned subsidiary of Aimmune Therapeutics (Bermuda) Ltd, a company incorporated in Bermuda.

Aimmune Therapeutics (Bermuda) Ltd is a 100% owned subsidiary of Aimmune Therapeutics Inc.

Aimmune Therapeutics Inc. is therefore considered to be the ultimate parent company.

The smallest group in which the results of the company are consolidated is that headed by Aimmune Therapeutics Inc.. The registered office of Aimmune Therapeutics Inc. is 8000 Marina Boulevard, Suite 300, Brisbane, California 94005, United States of America.

12. Auditor's information

The auditor's report on the financial statements for the year ended 31 December 2017 was unqualified.

The audit report was signed on 12/12/18 by Russel Byrd FCA FCCA (Senior statutory auditor) on behalf of Randall and Payne LLP.